SunRISe-1: Phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin who are ineligible for or decline radical cystectomy
Van Der Heijden, Michiel Simon, Cutie, Christopher, Hampras, Shalaka, Indoria, Charu, Stewart, Rachel, Acharya, Milin, Stromberg, Katherine, Li, Xiang, Beeharry, Neil, Maffeo, John, Jacob, Joseph M
Published in Journal of clinical oncology (20.02.2022)
Published in Journal of clinical oncology (20.02.2022)
Get full text
Journal Article